Research Education

PerformanceLabsUK supplies independently tested research reference materials for in vitro laboratory and scientific research use only, not for human or veterinary use.

GLP-1, GIP and Glucagon Receptor Agonists in Metabolic Research

Metabolic Research

Research use only. This article is educational and summarises findings from published academic literature. It is not medical advice and does not endorse the use of any compound for therapeutic or human consumption purposes. All materials referenced are supplied by PerformanceLabsUK for in vitro laboratory and scientific research use only, not for human or veterinary use.

GLP-1, GIP and glucagon receptor agonists are among the most widely studied compound classes in metabolic research. Published literature spans receptor binding, glucose handling models and energy expenditure pathways. This article summarises what that research examines, not how any compound might be used.

What are GLP-1, GIP and glucagon receptor agonists?

These are peptide compounds studied for their interaction with receptors involved in glucose and energy metabolism. GLP-1 (glucagon-like peptide-1) receptor agonists engage a receptor expressed in the pancreas, gut and central nervous system. GIP (glucose-dependent insulinotropic polypeptide) receptor agonists act on a related but distinct receptor pathway. Some research compounds, including tirzepatide-class and retatrutide-class molecules, are studied for combined action across GLP-1, GIP and glucagon receptors simultaneously, which is why the published literature often describes them as multi-receptor agonists.

What does metabolic receptor agonist research explore?

Receptor binding and selectivity — how strongly and specifically a compound binds to each receptor subtype.
Energy expenditure pathways — the downstream cellular signalling triggered by receptor activation.
Glucose handling models — in vitro and animal models used to observe receptor-mediated glucose uptake.
Comparative agonist research — how single-receptor and multi-receptor compounds differ in their studied mechanisms.

How advanced is the human research?

Human clinical research into GLP-1 and multi-receptor agonists has expanded significantly in the published literature over the past decade, with GIP/GLP-1 dual agonists reaching later-stage clinical trials for metabolic endpoints. Triple agonists such as retatrutide-class molecules are studied at an earlier stage, with published data concentrated in trial-registry findings and peer-reviewed early-phase results. PerformanceLabsUK supplies these compounds strictly as research reference material for laboratory use, not for human administration.

Comparing single and multi-receptor agonist research

Compound class	Receptors studied	Research stage (published literature)
GLP-1 selective agonists	GLP-1 receptor	Extensive, multi-phase clinical literature
GIP/GLP-1 dual agonists	GIP + GLP-1 receptors	Later-stage clinical research published
GIP/GLP-1/glucagon triple agonists (e.g. retatrutide-class)	GIP + GLP-1 + glucagon receptors	Early-to-mid-stage published research

Research context as reference material

PerformanceLabsUK supplies GLP-1, GIP and glucagon receptor agonist research compounds as independently tested research reference material, accompanied by a batch-specific Certificate of Analysis. These materials are supplied strictly for in vitro laboratory and scientific research use, not for human or veterinary use.

Frequently asked questions

Are these compounds tested before dispatch?

Yes. Every batch is independently tested, and a batch-specific Certificate of Analysis is available for the compounds we supply.

Are these compounds intended for human use?

No. All compounds are supplied strictly for in vitro laboratory and scientific research use, not for human or veterinary use.

Is this article medical advice?

No. This article summarises published academic research. It is educational only and does not constitute medical advice.

Where can I find batch-specific testing documentation?

Batch-specific Certificates of Analysis are published in our COA library and can be matched to the batch code on the product label.

Why are GIP, GLP-1 and glucagon compounds studied together in some research?

Published research groups these receptor targets together because several compounds are engineered to act on more than one receptor at once, and researchers compare combined receptor activity against single-receptor agonists to understand differences in studied metabolic pathways.

Research content only. PerformanceLabsUK Ltd, company number SC883220, registered in Scotland.